sars-cov-2 specific t cells

Cell therapyexperimental

Clinical trial activity

3 trials · 13 clinical orgs · 0 marketing orgs

Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0

Earliest trial started Jul 1, 2020 (NCT04457726)

Timeline

2020s

  1. Jan 1, 2020

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

  • SARS-CoV-2Immunity, passive

    SARS-CoV-2 immunity, passive

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT04762186Phase 1/Phase 2 (Phase 2)Apr 1, 2021Gottfried Wilhelm Leibniz Universität Hannover, Miltenyi Biotec, Inc., MMH Institute for Transfusion Medicine, University of Cologne, ZKS Köln
NCT04742595Early Phase 1 (Phase 1)Dec 18, 2020University of Texas at Houston
NCT04457726Phase 1/Phase 2 (Phase 2)Jul 1, 2020Changi General Hospital, Duke University, KK Women's and Children's Hospital, National University of Singapore, Sengkang General Hospital, Singapore General Hospital, SingHealth Investigational Medicine Unit
Showing 3 of 3 trials
Page 1 / 1

Organizations

Research & Development (13)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Changi General HospitalAcademic/Hospital1012020
Duke UniversityAcademic/Hospital1012020
Gottfried Wilhelm Leibniz Universität HannoverAcademic/Hospital1012021
KK Women's and Children's HospitalAcademic/Hospital1112020
Miltenyi Biotec, Inc.For profit1012021
MMH Institute for Transfusion MedicineAcademic/Hospital1012021
National University of SingaporeAcademic/Hospital1012020
Sengkang General HospitalAcademic/Hospital1012020
Singapore General HospitalAcademic/Hospital1012020
SingHealth Investigational Medicine UnitFor profit1012020
University of CologneAcademic/Hospital1112021
University of Texas at HoustonAcademic/Hospital1112020
ZKS KölnAcademic/Hospital1012021
13 organizations
Page 1 / 1